Close this search box.

New Cell Lines Enable Production of NISTmAb


NiimblAR-Pg.14-final_Dropper in beakerv2.png



new paper published in the journal mAbs describes how researchers at the Institute for Bioscience and Biotechnology Research (IBBR), a joint institute of NIST and the University of Maryland have engineered three mouse cell lines to produce nonproprietary versions of NISTmAb that closely resemble the characteristics of the original reference material. This discovery is an important step in improving the manufacturing process of biologic drugs used to fight health conditions such as cancer, autoimmune disorders, and infectious diseases.


Read the full story via NIST.

Become a member

We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.

Join Our Mailing List

MailChimp NIIMBL Mailing List Signup
Organization Type
How did you first hear about NIIMBL?